Project Grant HT9425261E096
Award Date 5/1/26
Completion Date 4/30/29
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- Federal Grant Award Summary The University of Washington received a $1,494,943 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026 through March 31, 2029. The award supports research and development services focused on biomaterial strategies to improve the specificity and efficacy of Chimeric Antigen Receptor (CAR) T cell therapy for breast cancer treatment. This research initiative aligns...
- The U.S. Defense Health Agency awarded a $1,965,204 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the University of Washington to support the early-stage development of an anti-inflammatory melanocortin fusion protein for tactical combat casualty care. The award period runs from August 1, 2024 to July 31, 2027. This research aims to investigate new therapeutic approaches for improving health outcomes for military service members. As a prominent...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a $4,876,076 Project Grant on August 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to develop a novel point-of-care (POC) multiplex device for classifying molecular phenotypes of acute respiratory distress syndrome and sepsis. The four-year award, extending through July 31, 2029, supports research and development of an innovative diagnostic technology...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- Federal Project Grant Award Summary The University of Virginia received a $1.7M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded May 1, 2026, with completion scheduled for April 30, 2029. This award supports research focused on preserving lung integrity and harnessing inflammation to treat burn-induced inhalation injury. The research will be conducted at the university's Charlottesville, Virginia campus and is...
- Federal Project Grant Award Summary Mainehealth received a $2.2 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 15, 2025, through June 14, 2028. The award funds research investigating the efficacy of tranexamic acid to reduce capillary leak, tissue edema, and fluid resuscitation requirements following severe burn injury. This research directly supports the DHA's mission to advance biomedical...
- Federal Grant Award Summary The Washington University was awarded $500,000 in Project Grant funding from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025 through July 31, 2027. The award supports research titled "Harnessing Single-Cell T Cell-Receptor Sequencing to Accelerate Diagnosis in Inflammatory Arthritis," to be conducted at the university's University City, Missouri campus. This research project...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a $699,751 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2026, with a completion date of April 30, 2029. The award funds research to unveil mechanisms and develop innovative therapeutic interventions targeting ESR1-CCDC170 fusions in clinically aggressive, endocrine-resistant, and metastatic breast cancers. This research initiative represents the DHA's...
- Federal Grant Award Summary The University of Wisconsin-Madison received a $729,778 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) beginning June 1, 2025 and concluding May 31, 2028. The award supports multiomic analysis of liquid biopsies for biomarker discovery and therapeutic targeting—research aimed at identifying and developing novel diagnostic markers and treatment approaches through comprehensive molecular...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded the University of Wisconsin–Madison a $1,074,650 project grant under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, with an ultimate completion date of August 31, 2029. The grant supports investigation of the immunomodulatory effects of chemokine signaling in renal cell carcinoma, representing a hypothesis-driven biomedical research initiative designed to advance innovative...